Claims
- 1. A method of inhibiting proliferation of vascular smooth muscle cells at the venous outflow tract of an arteriovenous shunt or fistula comprising introducing into said cells an inhibitor of Gβγ-mediated processes in an amount and under conditions such that said inhibition of vascular smooth muscle cell proliferation is effected.
- 2. The method according to claim 1 wherein said inhibitor is a polypeptide.
- 3. The method according to claim 2 wherein said polypeptide inhibits binding of β adrenergic receptor kinase (βARK) to Gβγ.
- 4. The method according to claim 3 wherein said polypeptide corresponds to the βARK Gβγ binding domain.
- 5. The method according to claim 4 wherein said polypeptide has the amino acid sequence set forth in SEQ ID NO:2 or portion thereof that includes at least amino acids 150-177 of said SEQ ID NO:2 sequence.
- 6. The method according to claim 2 wherein a nucleic acid sequence encoding said polypeptide is introduced into said cells under conditions such that said nucleic acid is expressed and said polypeptide is thereby produced.
- 7. The method according to claim 6 wherein said polypeptide inhibits binding of β adrenergic receptor kinase (βARK) to Gβγ.
- 8. The method according to claim 7 wherein said polypeptide corresponds to the βARK Gγβ binding domain.
- 9. The method according to claim 8 wherein said polypeptide has the amino acid sequence set forth in SEQ ID NO:2 or portion thereof that includes at least amino acids 150-177 of said SEQ ID NO:2 sequence.
- 10. The method according to claim 6 wherein said nucleic acid is present in a vector.
- 11. The method according to claim 10 wherein said vector is a viral vector.
- 12. The method according to claim 11 wherein said vector is an adenoviral vector.
- 13. The method according to claim 1 wherein said Gβγ-mediated process is Gβγ-mediated proliferative signaling.
- 14. A method of manufacturing a stent or shunt comprising bonding to, or incorporating into, a stent or shunt an agent that inhibits proliferation of cells at risk of proliferation upon implantation into a patient of said stent or shunt, said agent being an inhibitor of Gβγ-mediated processes.
- 15. The method according to claim 1 wherein said cells are vascular smooth muscle cells.
Parent Case Info
[0001] This application is a continuation-in-part of application Ser. No. 09/400,861, filed Sep. 21, 1999, which is a continuation of application Ser. No. 08/943,208, filed Oct. 3, 1997, now U.S. Pat. No. 5,981,487.
Continuations (1)
|
Number |
Date |
Country |
Parent |
08943208 |
Oct 1997 |
US |
Child |
09400861 |
Sep 1999 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09400861 |
Sep 1999 |
US |
Child |
10262661 |
Oct 2002 |
US |